Zurich Cantonal Bank’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-32,961
| Closed | -$100K | – | 2707 |
|
|
2024
Q4 | $100K | Hold |
32,961
| – | – | ﹤0.01% | 2435 |
|
|
2024
Q3 | $171K | Hold |
32,961
| – | – | ﹤0.01% | 2194 |
|
|
2024
Q2 | $84.7K | Buy |
32,961
+10,638
| +48% | +$36.3K | ﹤0.01% | 2436 |
|
|
2024
Q1 | $110K | Buy |
22,323
+4,240
| +23% | +$25.1K | ﹤0.01% | 2362 |
|
|
2023
Q4 | $159K | Hold |
18,083
| – | – | ﹤0.01% | 2216 |
|
|
2023
Q3 | $207K | Buy |
18,083
+2,622
| +17% | +$50.4K | ﹤0.01% | 1961 |
|
|
2023
Q2 | $391K | Buy |
15,461
+1,134
| +8% | +$35.3K | ﹤0.01% | 1504 |
|
|
2023
Q1 | $461K | Buy |
14,327
+456
| +3% | +$14.2K | ﹤0.01% | 1331 |
|
|
2022
Q4 | $256K | Buy |
13,871
+5,989
| +76% | +$137K | ﹤0.01% | 1678 |
|
|
2022
Q3 | $213K | Hold |
7,882
| – | – | ﹤0.01% | 1716 |
|
|
2022
Q2 | $109K | Hold |
7,882
| – | – | ﹤0.01% | 2172 |
|
|
2022
Q1 | $154K | Hold |
7,882
| – | – | ﹤0.01% | 2060 |
|
|
2021
Q4 | $129K | Hold |
7,882
| – | – | ﹤0.01% | 2371 |
|
|
2021
Q3 | $220K | Hold |
7,882
| – | – | ﹤0.01% | 1863 |
|
|
2021
Q2 | $234K | Hold |
7,882
| – | – | ﹤0.01% | 1712 |
|
|
2021
Q1 | $220K | Hold |
7,882
| – | – | ﹤0.01% | 1723 |
|
|
2020
Q4 | $223K | Hold |
7,882
| – | – | ﹤0.01% | 1779 |
|
|
2020
Q3 | $198K | Hold |
7,882
| – | – | ﹤0.01% | 1596 |
|
|
2020
Q2 | $192K | Buy |
7,882
+4,075
| +107% | +$80.4K | ﹤0.01% | 1552 |
|
|
2020
Q1 | $56K | Buy |
3,807
+1,080
| +40% | +$22.3K | ﹤0.01% | 1896 |
|
|
2019
Q4 | $44K | Hold |
2,727
| – | – | ﹤0.01% | 2217 |
|
|
2019
Q3 | $35K | Buy |
2,727
+1,262
| +86% | +$15.4K | ﹤0.01% | 2249 |
|
|
2019
Q2 | $19K | Hold |
1,465
| – | – | ﹤0.01% | 2478 |
|
|
2019
Q1 | $23K | Sell |
1,465
-887
| -38% | -$15.4K | ﹤0.01% | 2379 |
|
|
2018
Q4 | $47K | Buy |
2,352
+1,159
| +97% | +$25.5K | ﹤0.01% | 2075 |
|
|
2018
Q3 | $30K | Hold |
1,193
| – | – | ﹤0.01% | 2375 |
|
|
2018
Q2 | $33K | Hold |
1,193
| – | – | ﹤0.01% | 2312 |
|
|
2018
Q1 | $37K | Hold |
1,193
| – | – | ﹤0.01% | 2228 |
|
|
2017
Q4 | $43K | Buy |
1,193
+813
| +214% | +$23.3K | ﹤0.01% | 2156 |
|
|
2017
Q3 | $10K | Hold |
380
| – | – | ﹤0.01% | 2426 |
|
|
2017
Q2 | $10K | Hold |
380
| – | – | ﹤0.01% | 2430 |
|
|
2017
Q1 | $8K | Hold |
380
| – | – | ﹤0.01% | 2516 |
|
|
2016
Q4 | $8K | Hold |
380
| – | – | ﹤0.01% | 2487 |
|
|
2016
Q3 | $6K | Hold |
380
| – | – | ﹤0.01% | 2507 |
|
|
2016
Q2 | $5K | Hold |
380
| – | – | ﹤0.01% | 2499 |
|
|
2016
Q1 | $7K | Hold |
380
| – | – | ﹤0.01% | 2471 |
|
|
2015
Q4 | $13K | Hold |
380
| – | – | ﹤0.01% | 2290 |
|
|
2015
Q3 | $11K | Buy |
+380
| New | +$11.5K | ﹤0.01% | 1924 |
|
|
2014
Q3 | – | Sell |
-130,000
| Closed | -$4.42M | – | 994 |
|
|
2014
Q2 | $4.42M | Buy |
130,000
+30,000
| +30% | +$940K | 0.13% | 187 |
|
|
2014
Q1 | $3.15M | Buy |
+100,000
| New | +$3.12M | 0.1% | 240 |
|
Other funds holding RVNC
Zurich Cantonal Bank's RVNC Position: Q1 2025 in Review
Zurich Cantonal Bank sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 32,961 shares — an estimated $100K sold.
Zurich Cantonal Bank first reported a position in RVNC in Q1 2014 and held it in 40 quarters. The position peaked at $4.42M in Q2 2014. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Zurich Cantonal Bank reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Zurich Cantonal Bank sold 32,961 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $100K.
- Zurich Cantonal Bank first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 40 quarters.
- Zurich Cantonal Bank's Revance Therapeutics, Inc. position peaked at $4.42M in Q2 2014.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Zurich Cantonal Bank's 13F filing for Q1 2025, filed 7 May 2025.